Aeglea BioTherapeutics Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aeglea BioTherapeutics stock.
View analyst ratings for Aeglea BioTherapeutics or view top-rated stocks.

Wall Street analysts have given Aeglea BioTherapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aeglea BioTherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Aeglea BioTherapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Aeglea BioTherapeutics.

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) posted its earnings results on Sunday, May, 9th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.11.
View Aeglea BioTherapeutics' earnings history.

Aeglea BioTherapeutics' stock was trading at $5.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AGLE stock has increased by 19.7% and is now trading at $6.44.
View which stocks have been most impacted by COVID-19.

3 equities research analysts have issued 12-month target prices for Aeglea BioTherapeutics' shares. Their forecasts range from $11.00 to $15.00. On average, they expect Aeglea BioTherapeutics' stock price to reach $13.00 in the next year. This suggests a possible upside of 101.9% from the stock's current price.
View analysts' price targets for Aeglea BioTherapeutics or view top-rated stocks among Wall Street analysts.

3 employees have rated Aeglea BioTherapeutics CEO Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among Aeglea BioTherapeutics' employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Aeglea BioTherapeutics include Repare Therapeutics (RPTX), Vectura Group (VEGPF), DiaMedica Therapeutics (DMCAF), Keros Therapeutics (KROS), Shattuck Labs (STTK), Endo International (ENDP), Phibro Animal Health (PAHC), Antibe Therapeutics (ATBPD), CytoDyn (CYDY), Theravance Biopharma (TBPH), Dyne Therapeutics (DYN), Phathom Pharmaceuticals (PHAT), Humanigen (HGEN), Vanda Pharmaceuticals (VNDA) and MannKind (MNKD).
View all of AGLE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aeglea BioTherapeutics investors own include Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Kura Oncology (KURA), Aduro Biotech (ADRO), Axsome Therapeutics (AXSM), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX) and Dicerna Pharmaceuticals (DRNA).

(AGLE) raised $60 million in an IPO on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager.

Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE."

Aeglea BioTherapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.83%), Nantahala Capital Management LLC (3.49%), Rock Springs Capital Management LP (3.22%), Point72 Asset Management L.P. (3.06%), Suvretta Capital Management LLC (2.79%) and Goldman Sachs Group Inc. (2.32%).
View institutional ownership trends for Aeglea BioTherapeutics.

AGLE stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Nantahala Capital Management LLC, Millennium Management LLC, Russell Investments Group Ltd., D. E. Shaw & Co. Inc., Renaissance Technologies LLC, Algert Global LLC, and Northern Trust Corp.
View insider buying and selling activity for Aeglea BioTherapeutics or view top insider-selling stocks.

AGLE stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Suvretta Capital Management LLC, Great Point Partners LLC, BlackRock Inc., Geode Capital Management LLC, Axiom Investment Management LLC, Axiom Investment Management LLC, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Aeglea BioTherapeutics or or view top insider-buying stocks.

Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AGLE stock can currently be purchased for approximately $6.44.

Aeglea BioTherapeutics has a market capitalization of $315.71 million and generates $3.89 million in revenue each year. The biotechnology company earns $-80,890,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis.

Aeglea BioTherapeutics employs 88 workers across the globe.

The official website for Aeglea BioTherapeutics is www.aegleabio.com.

Aeglea BioTherapeutics is headquartered at 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746.

Aeglea BioTherapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-942-2935 or via email at [email protected]